(Q39969339)

16 September 2017

The incorporation of APOBEC3 proteins into murine leukemia viruses (English)

1 reference

16 September 2017

1 reference

Li Zhang

1

1 reference

16 September 2017

Xiaoyu Li

2

1 reference

16 September 2017

Jing Ma

3

1 reference

16 September 2017

Liyan Yu

4

1 reference

16 September 2017

Jiandong Jiang

5

1 reference

16 September 2017

Shan Cen

6

1 reference

16 September 2017

language of work or name

English

0 references

publication date

24 June 2008

1 reference

16 September 2017

1 reference

16 September 2017

378

1 reference

16 September 2017

69-78

1 reference

16 September 2017

1

1 reference

Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms.

16 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Antiviral potency of APOBEC proteins does not correlate with cytidine deamination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Species-specific restriction of apobec3-mediated hypermutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

The interaction between HIV-1 Gag and APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Incorporation of pol into human immunodeficiency virus type 1 Gag virus-like particles occurs independently of the upstream Gag domain in Gag-pol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

DNA deamination mediates innate immunity to retroviral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Complementary function of the two catalytic domains of APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

APOBEC3 inhibits mouse mammary tumour virus replication in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

APOBEC-mediated interference with hepadnavirus production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Inhibition of hepatitis B virus replication by APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

APOBEC3G incorporation into human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.05.006

10.1016/J.VIROL.2008.05.006

7 January 2021

Identifiers

DOI

1 reference

16 September 2017

1 reference